Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2NIH 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 513Neoplasms 381Lymphoma 341Prostatic Neoplasms 291Melanoma 284Carcinoma, Non-Small-Cell Lung 278Precursor Cell Lymphoblastic Leukemia-Lymphoma 264Lung Neoplasms 257Leukemia, Lymphocytic, Chronic, B-Cell 249Leukemia, Myeloid, Acute 236Leukemia 235Lymphoma, Non-Hodgkin 227Colonic Neoplasms 226Ovarian Neoplasms 208Lymphoma, Large B-Cell, Diffuse 208Multiple Myeloma 207Brain Neoplasms 206Colorectal Neoplasms 203Lymphoma, Follicular 201Rectal Neoplasms 194Burkitt Lymphoma 183Neoplasm Metastasis 180Carcinoma, Renal Cell 172Glioblastoma 169Sarcoma 168Lymphoma, Mantle-Cell 166Pancreatic Neoplasms 158Lymphoma, B-Cell, Marginal Zone 145Unspecified Adult Solid Tumor, Protocol Specific 141Hodgkin Disease 141

Interventions

Ranibizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Macular Edema × Clear all
NCT00089765 2017-07-02

Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
5 enrolled

von Hippel-Lindau Disease, Macular Edema, Neoplasms

NCT00056199 2008-03-04

EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
5 enrolled

von Hippel-Lindau Disease, Macular Edema, Vision Disorders, Optic Nerve Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡